Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (NASDAQ: BNGO) has announced significant upgrades to its software platforms VIA™ 7.2 and Solve™ 3.8.3, along with enhancements to its Stratys™ Compute server. The updates focus on improving the analysis of optical genome mapping (OGM), microarray, and NGS data.
Key improvements include AI-powered workflow transformation for constitutional genetic disorders, an 18% expansion of the structural variants control database, and the ability to double the number of cancer samples analyzed per week. The software releases will initially be available to 20 early access users, with broad commercial release expected in Q4 2025.
The upgrades introduce significance associated with phenotype (SAP) scoring for OGM data and enhance the system's ability to learn from historical lab results, improving interpretation speed and accuracy.
Bionano Genomics (Nasdaq: BNGO) has scheduled its second quarter 2025 financial results conference call and webcast for August 14, 2025, at 4:30 p.m. Eastern Time. The company will present its Q2 2025 financial performance and provide updates on recent corporate developments.
Investors and interested parties can access the live webcast through the company's investor relations website. A replay of the presentation will be available for at least 30 days after the event on Bionano's IR website at ir.bionano.com.
Bionano Genomics (NASDAQ: BNGO) showcased significant momentum for its Optical Genome Mapping (OGM) technology at the 2025 European Cytogenomics Association (ECA) conference in Leuven, Belgium. The event featured 16 scientific studies from seven countries, marking an increase from 14 studies in 2023 and 9 in 2021.
The conference included two hands-on workshops focused on VIA™, Bionano's analytical suite for structural variation analysis, led by key opinion leaders from Belgium and France. Research presentations covered applications in multiple myeloma, non-Hodgkin lymphoma, and various genetic disorders, demonstrating OGM's growing adoption in clinical cytogenomics research across Europe and the Middle East.
Bionano Genomics (NASDAQ: BNGO) has scheduled its first quarter 2025 financial results conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time. The company will present its Q1 2025 financial performance and provide updates on recent corporate developments. Investors and interested parties can access the live webcast through the company's investor relations website, where a replay will be available for at least 30 days following the presentation.
Bionano Genomics (BNGO) has published a peer-reviewed study in Genome Research demonstrating the effectiveness of optical genome mapping (OGM) in detecting large repeat expansions linked to genetic disorders. The research, conducted at Radboud University Medical Center, evaluated 85 subjects with known pathogenic expansions in three genes associated with myotonic dystrophy and CANVAS syndrome.
The study revealed key findings:
- 98.8% detection accuracy (84 out of 85 cases)
- Accurate measurement of repeat sizes, even exceeding 7,000 units
- Detection of somatic instability in 36 out of 85 samples
- Single comprehensive assay capability across multiple loci
The research suggests OGM could provide a more cost-effective and efficient alternative to traditional methods like PCR, Southern blotting, and next-generation sequencing for analyzing repeat expansions in genetic disorders.
Bionano Genomics (BNGO) has announced a breakthrough study published in The Journal of Molecular Diagnostics regarding the analysis of multiple myeloma (MM) using optical genome mapping (OGM). The research, conducted at Lille University Hospital, France, demonstrates an innovative method that reduces the required number of CD138-positive cells by half for MM analysis.
The study revealed that mixing CD138-positive and negative cells in a 1:1 ratio is sufficient for OGM analysis, requiring only 0.5 million CD138-positive cells instead of the typical 1 million. The method achieved 93% concordance with traditional FISH testing while detecting 22 additional genetic variants. This advancement streamlines laboratory workflows by consolidating multiple tests into a single comprehensive approach and improves prognostic risk evaluation through more detailed genomic profiling.
Bionano Genomics (BNGO) reported Q4 2024 financial results with total revenue of $8.2 million, down 24% from Q4 2023. Full-year 2024 revenue was $30.8 million, a 15% decrease from 2023. Despite challenges, the company achieved a 42% GAAP gross margin in Q4 2024, up from 23% in Q4 2023.
Key operational highlights include:
- Installed base grew 14% to 371 OGM systems
- Flowcell sales increased 15% to 30,307 units in 2024
- Published 336 OGM publications, up 19% from 2023
The company provided 2025 guidance of $29.0-$32.0 million in revenue and plans to install 15-20 new OGM systems. Cost reduction efforts have decreased annualized operating expenses by approximately $100 million. Cash runway extends into Q1 2026, supported by recent financing activities including a $10 million Registered Direct Offering in January 2025.
Bionano Genomics (BNGO) and Greenwood Genetic Center published groundbreaking research in Genome Research using optical genome mapping (OGM) to study neural tube defects (NTDs). The study analyzed 104 NTD cases, revealing significant findings:
The research detected:
- Pathogenic structural variants in 8% of cases (8/104)
- Variants affecting known NTD pathway genes in 13% of cases (14/104)
- Variants affecting NTD-associated genes from mouse models in 9% of cases (9/104)
The study identified four novel candidate genes (RMND5A, HNRNPC, FOXD4, and RBBP4) potentially linked to NTDs and expanded clinical implications for AMER1 and TGIF1. With NTDs affecting approximately 300,000 births annually worldwide, this research provides new insights into genetic factors in 30% of combined cases, potentially improving future patient management and therapeutic interventions.